CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
about
CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patientsDose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit allPerspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbiditiesPharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6Efavirenz and the CNS: what we already know and questions that need to be answeredInfluence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patientsCYP2B6 gene single nucleotide polymorphisms and leukemia susceptibilityEffect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV InfectionEfavirenz in the therapy of HIV infection.Genetic variation in the CYP2B6 gene is related to circulating 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) concentrations: an observational population-based study.Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practiceIsoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6.Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents?Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylationHaplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort.Liver autophagy in anorexia nervosa and acute liver injuryABCB1 variation and treatment response in AIDS patients: initial results of the Henan cohortViral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimenContribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz.Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.Pharmacogenomics of antimicrobial agents.Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteersPharmacogenetics in Ghana: reviewing the evidence.Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.A Global Health Diagnostic for Personalized Medicine in Resource-Constrained World Settings: A Simple PCR-RFLP Method for Genotyping CYP2B6 g.15582C>T and Science and Policy Relevance for Optimal Use of Antiretroviral Drug Efavirenz.Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE studyIndividualization of antiretroviral therapy.Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice.Clinical pharmacokinetics of antiretroviral drugs in older persons.Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6Pharmacology, basic & clinical: contrasts & coherenceThe influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosisPhysiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans.Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo.
P2860
Q24606937-DADDC7D8-132E-4B67-85B0-EC8210CD6FC6Q24609011-C20AFAFB-5384-451B-A615-842341D43EDAQ26853274-F348C32E-04F8-446A-B7CC-8DD2ED8D7262Q27012807-31C5BC0E-4A11-4563-9A5E-225EE954013FQ28085028-53783208-580E-4A18-B607-138563D59FD9Q28293875-01A88085-D0BE-4606-9C7F-4A0194D0FA52Q28294323-C787B014-C6A7-445A-B22E-507D6BAD9808Q28548638-2486F89E-7B24-4600-A3DD-634D69E7F729Q33607011-B6244FAC-A49E-4483-97F2-CFE918DEC52DQ33626302-F661DCF0-2BB3-4C04-9B95-A83731BA99A3Q33681426-7A6C8F59-0DA8-4397-A3B8-783686F316A6Q33798516-BA2A4A44-10BF-454D-B3E8-9B15C4EB84E2Q33909996-10A21CF2-A2CE-4CF2-9296-8B7BC6A29E3AQ33914723-7D02D2EC-1715-46A1-AC2D-A9DBA1AF26A3Q34015667-8631DE5A-36DD-4196-8928-523CD6096BB5Q34060396-67EDAD9F-4DE2-40F6-9C1A-5765CE583D94Q34177327-FC9B8E15-D48D-4144-A8D7-49A902885E84Q34571645-B39A41DA-85A5-4DDB-828B-0C4F0F57DB8EQ34699201-59FF6CD0-BEA5-4E6D-8D65-0761349D6E81Q34737523-01204C8E-6B99-4FF9-872A-850DA5148F42Q34975110-2270AD07-DCE1-4793-989B-801C791B5FF0Q34977413-FA607D37-58D7-498C-A697-BAD39F0C1547Q35065867-6B2A371D-4D77-45C0-B061-3FA58E8CDB5BQ35172002-DC035B0F-D8A8-44F7-A199-06FCCA0D09C4Q35364120-3C7C6E6C-32E2-43CA-8FF3-609FA8F38BC8Q35547723-CF980CAF-1EBA-49D0-B169-8477B82FA4C6Q35802412-8B339164-3C6E-49B3-B643-B440376FA24DQ35974648-2329856C-BC8C-4F0D-A9B8-FB2A4DE4A9AAQ36441423-F3D0B88A-90AC-4A02-86F9-5C9D81F62EF8Q36468146-CF5DEC38-7446-447A-9CF4-99970189A3BEQ36554279-A03DB0C0-24CA-4CDC-8A7E-FE3BB4B36D99Q36558327-1EB4273E-9C50-4C14-8292-54CAB2E237C2Q36801543-4B5F47F1-B2AA-4E37-982B-3E95A43F435BQ36905884-FE128896-5460-411C-8EE0-8CC8B01F4854Q37036991-E93381EE-CEDB-43DB-8BE5-DEB76CB5A0BBQ37126489-5B4B104C-8203-4461-9C30-A973E1C5F688Q37184408-D221E2F2-0F06-41E0-95BA-D76177791BD6Q37466856-95AFB51F-2C8E-408A-B836-FD25555D3391Q37498669-D90B5B9E-1BB0-4374-8661-421C796BE239Q37596743-9AC3DACA-ECAF-4575-AEBE-040F44D646F1
P2860
CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CYP2B6 (c.516G-->T) and CYP2A6 ...... ions in HIV-infected patients.
@en
CYP2B6
@nl
type
label
CYP2B6 (c.516G-->T) and CYP2A6 ...... ions in HIV-infected patients.
@en
CYP2B6
@nl
prefLabel
CYP2B6 (c.516G-->T) and CYP2A6 ...... ions in HIV-infected patients.
@en
CYP2B6
@nl
P2093
P2860
P1476
CYP2B6 (c.516G-->T) and CYP2A6 ...... ions in HIV-infected patients.
@en
P2093
Awewura Kwara
Kwamena W Sagoe
Margaret Lartey
Michael H Court
Naser L Rzek
P2860
P304
P356
10.1111/J.1365-2125.2009.03368.X
P407
P577
2009-04-01T00:00:00Z